About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
VRTX - Vertex Pharmaceutica...| Previous Close | $273.34 | Open | $273.48 |
| Volume | 1.01M | Market Cap | 71.196B |
| Yield | Last Dividend |
| Cramer Weighs In On Lumentum, American A... | 08/06/20 |
| On CNBC's "Mad Money Lightning Round," Jim Cramer said that Sarepta Therapeutics Inc (NASDAQ: SRPT ) is good and he would own it, but he prefers Verte... | |
| Fund manager Tom O'Halloran quadrupled i... | 08/04/20 |
| Thomas O'Halloran manages the Lord Abbett Growth Leaders Fund , which has more than quadrupled investors' money in nine years by investing in high-gro... | |
| Vertex Pharmaceuticals Inc. (VRTX) Q2 20... | 07/31/20 |
| Final earnings conference call transcript of Vertex Pharmaceuticals Inc. - VRTX stock | |
| Vertex Pharmaceuticals : Q2 2020 Present... | 07/30/20 |
| SECOND-QUARTER 2020 FINANCIAL RESULTS JULY 30, 2020 ??2020 Vertex Pharmaceuticals Incorporated ??? | July 31, 2020 | |
| Vertex Reports Second-Quarter 2020 Finan... | 07/30/20 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended... | |
| Vertex Pharmaceuticals For A Strong Port... | 07/27/20 |
| Vertex Pharmaceuticals owns a blockbuster drug, TRIKAFTA, which treats cystic fibrosis (CF). The company currently commands a monopoly in treating CF. | |
| Earnings For Vertex Pharmaceuticals Expe... | 07/27/20 |
| Vertex Pharmaceuticals is set to report earnings after the closing bell on Thursday. Earnings and revenue are expected to jump sharply compared to the... | |
| Credit Suisse Upgrades Gilead On Remdesi... | 07/20/20 |
| The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse. Biotechs... | |
| Positive Phase 3 Study Results for TRIKA... | 07/20/20 |
| BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA?? (ele... | |
| Vertex to Announce Second-Quarter 2020 F... | 07/16/20 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30... | |
| The Daily Biotech Pulse: Intersect ENT J... | 07/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbV... | |
| Vertex Pharmaceuticals : Gets Positive C... | 06/26/20 |
| By Colin Kellaher Vertex Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommende... | |
| CHMP Grants Positive Opinion for KAFTRIO... | 06/26/20 |
| LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency???s (EMA) Committee for... | |
| Vertex Pharmaceuticals (VRTX) Gains As M... | 06/10/20 |
| In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $274.34, marking a +1.29% move from the previous day. | |
| Vertex's Kalydeco Wins Approval in EU fo... | 06/10/20 |
| Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene. | |
| Vertex Announces European Commission App... | 06/10/20 |
| LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the l... | |
| Zacks Market Edge Highlights: Vertex Pha... | 06/04/20 |
| Zacks Market Edge Highlights: Vertex Pharmaceuticals, Channel Advisor, Gold Fields, AngloGold Ashanti and Dropbox | |
| Zacks.com featured highlights include: V... | 06/03/20 |
| Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply | |
| Vertex Pharmaceuticals Is a Biotech Play... | 06/02/20 |
| VRTX stock is a biopharmaceutical with an A-Rating that has no stake in the risky race for a coronavirus treatment. | |
| MORGAN STANLEY: Buy these 23 high-growth... | 05/28/20 |
| A team of Morgan Stanley equity analysts compiled a list of 23 high-growth, high-conviction stock picks they believe can outperform the market over th... | |
| Is Vertex Pharmaceuticals Stock a Buy? |... | 05/24/20 |
| This successful biotech has two big things going for it. | |
| The untold story of Moderna as the biote... | 05/23/20 |
| The biotech Moderna has skyrocketed to global prominence, leading the world's race for a coronavirus vaccine. The Cambridge, Massachusetts-based biote... | |
| The Zacks Analyst Blog Highlights: Chegg... | 05/20/20 |
| The Zacks Analyst Blog Highlights: Chegg, Quidel, MarketAxess, Dropbox and Vertex Pharmaceuticals | |
| The Zacks Analyst Blog Highlights: Chegg... | 05/20/20 |
| The Zacks Analyst Blog Highlights: Chegg, Nautilus Group, Sprouts Farmers Market, VeriSign and Vertex Pharmaceuticals | |
| The Zacks Analyst Blog Highlights: The H... | 05/19/20 |
| The Zacks Analyst Blog Highlights: The Hain Celestial Group, Murphy USA, Vertex Pharmaceuticals, Sprouts Farmers Market and ASE Technology | |
| The Daily Biotech Pulse: FDA Nod For Roc... | 05/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC ... | |
| The Daily Biotech Pulse: Gilead Signs Ma... | 05/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acce... | |
| Buy rating | 07/31/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $295.00 to $315.00 | |
| Buy rating | 07/31/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $263.00 to $274.00 | |
| Strong Buy rating | 07/31/20 |
| Cantor Fitzgerald maintains Overweight rating and raises Price Target from $293.00 to $305.00 | |
| Strong Buy rating | 07/20/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $298.00 to $328.00 | |
| Hold rating | 07/08/20 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and raises Price Target from $277.00 to $300.00 | |
| Buy rating | 06/24/20 |
| SunTrust Robinson Humphrey maintains Buy rating and raises Price Target from $285.00 to $330.00 | |
| Buy rating | 06/12/20 |
| Citigroup maintains Buy rating and raises Price Target from $305.00 to $325.00 | |
| Buy rating | 05/15/20 |
| Argus Research maintains Buy rating and raises Price Target from $270.00 to $320.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| AungPan Thar's Swing trading | Kyaw Aung | 65.00 % | Subscribe |
| TopFlight Trades - Premium (Options) | Eric Cunningham | 51.00 % | Follow |
| Optioneering-W | Sam Allen | 41.00 % | Follow |
| Symmetry Options | Symmetry Options | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
